Circ_0025033 deficiency suppresses paclitaxel resistance and malignant development of paclitaxel-resistant ovarian cancer cells by modulating the miR-532-3p/FOXM1 network

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
   PubMed Web of Science ®Google Scholar
• Singh A, Gupta S, Sachan M. Epigenetic biomarkers in the management of ovarian cancer: current prospectives. Front Cell Dev Biol. 2019;7:182.
   PubMed Web of Science ®Google Scholar
• Kampan NC, Madondo MT, McNally OM, et al. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015;2015:413076.
   PubMed Web of Science ®Google Scholar
• Morgan RJ, Alvarez RD, Armstrong DK, et al.r. National Comprehensive Cancer Network, et al. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012;10(11):1339–1349.
   PubMed Web of Science ®Google Scholar
• Yang H, Mao W, Rodriguez-Aguayo C, et al. Paclitaxel sensitivity of ovarian cancer can be enhanced by knocking down pairs of kinases that regulate MAP4 phosphorylation and microtubule stability. Clin Cancer Res. 2018;24(20):5072–5084.
   PubMed Web of Science ®Google Scholar
• Hall M, Gourley C, McNeish I, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013;108(2):250–258.
   PubMed Web of Science ®Google Scholar
• Zhao ZJ, Shen J. Circular RNA participates in the carcinogenesis and the malignant behavior of cancer. RNA Biol. 2017;14(5):514–521.
   PubMed Web of Science ®Google Scholar
• Cui C, Yang J, Li X, et al. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Mol Cancer. 2020;19(1):58.
   PubMed Web of Science ®Google Scholar
• Xu N, Chen S, Liu Y, et al. Profiles and bioinformatics analysis of differentially expressed circRNAs in Taxol-resistant non-small cell lung cancer cells. Cell Physiol Biochem. 2018;48(5):2046–2060.
   PubMedGoogle Scholar
• Zhang S, Cheng J, Quan C, et al. circCELSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252. Mol Ther Nucleic Acids. 2020;19:718–730.
   PubMedGoogle Scholar
• Pan Y, Xu T, Liu Y, et al. Upregulated circular RNA circ_0025033 promotes papillary thyroid cancer cell proliferation and invasion via sponging miR-1231 and miR-1304. Biochem Biophys Res Commun. 2019;510(2):334–338.
   PubMed Web of Science ®Google Scholar
• Staicu CE, Predescu D-V, Rusu CM, et al. Role of microRNAs as clinical cancer biomarkers for ovarian cancer: a short overview. Cells. 2020;9(1):169.
   Web of Science ®Google Scholar
• Kulcheski FR, Christoff AP, Margis R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238:42–51.
   PubMed Web of Science ®Google Scholar
• Bai S, Wu Y, Yan Y, et al. Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma. Sci Rep. 2020;10(1):13659.
   PubMed Web of Science ®Google Scholar
• Liang L, Zhang L, Zhang J, et al. Identification of circRNA-miRNA-mRNA networks for exploring the fundamental mechanism in lung adenocarcinoma. Onco Targets Ther. 2020;13:2945–2955.
   PubMed Web of Science ®Google Scholar
• Gu C, Cai J, Xu Z, et al. MiR-532-3p suppresses colorectal cancer progression by disrupting the ETS1/TGM2 axis-mediated Wnt/β-catenin signaling. Cell Death Dis. 2019;10(10):739.
   PubMedGoogle Scholar
• Zhou Y, Zheng X, Lu J, et al. Ginsenoside 20(S)-Rg3 inhibits the Warburg effect via modulating DNMT3A/ MiR-532-3p/HK2 pathway in ovarian cancer cells. Cell Physiol Biochem. 2018;45(6):2548–2559.
   PubMedGoogle Scholar
• Pan H, Zhu Y, Wei W, et al. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer. World J Surg Oncol. 2018;16(1):59.
   PubMedGoogle Scholar
• Breyer J, Wirtz RM, Erben P, et al. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. BJU Int. 2019;123(1):187–196.
   PubMed Web of Science ®Google Scholar
• Westhoff GL, Chen Y, Teng NNH. Targeting FOXM1 improves cytotoxicity of paclitaxel and cisplatinum in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2017;27(8):1602–1609.
   PubMed Web of Science ®Google Scholar
• Wen N, et al. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer. J Transl Med. 2014;12:134.
   PubMed Web of Science ®Google Scholar
• Xiong W, Ai Y-Q, Li Y-F, et al. Microarray analysis of circular RNA expression profile associated with 5-fluorouracil-based chemoradiation resistance in colorectal cancer cells. Biomed Res Int. 2017;2017:8421614.
   PubMed Web of Science ®Google Scholar
• Kun-Peng Z, Xiao-Long M, Lei Z, et al. Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics. 2018;10(10):1327–1346.
   PubMed Web of Science ®Google Scholar
• Ye M, Hou H, Shen M, et al. Circular RNA circFOXM1 plays a role in papillary thyroid carcinoma by sponging miR-1179 and regulating HMGB1 expression. Mol Ther Nucleic Acids. 2020;19:741–750.
   PubMedGoogle Scholar
• Zhang M, Xia B, Xu Y, et al. Circular RNA (hsa_circ_0051240) promotes cell proliferation, migration and invasion in ovarian cancer through miR-637/KLK4 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):1224–1233.
   PubMed Web of Science ®Google Scholar
• Jiang W, Zheng L, Yan Q, et al. MiR-532-3p inhibits metastasis and proliferation of non-small cell lung cancer by targeting FOXP3. J Buon. 2019;24(6):2287–2293.
   PubMed Web of Science ®Google Scholar
• Wa Q, Zou C, Lin Z, et al. Ectopic expression of miR-532-3p suppresses bone metastasis of prostate cancer cells via inactivating NF-κB Signaling. Mol Ther Oncolytics. 2020;17:267–277.
   PubMed Web of Science ®Google Scholar
• Zhao F, Siu MKY, Jiang LLi, et al. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLOS One. 2014;9(11):e113478.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang Y, Wang Y, et al. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLOS One. 2014;9(5):e96989.
   PubMed Web of Science ®Google Scholar